Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia (THETIS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01709838 |
|
Recruitment Status :
Completed
First Posted : October 18, 2012
Results First Posted : August 28, 2019
Last Update Posted : October 2, 2019
|
Sponsor:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
Assessed the efficacy of deferasirox in patients with non-transfusion dependent thalassemia based on change in liver iron concentration from baseline after 52 weeks of treatment. Provided further assessment of the long-term efficacy and safety of deferasirox in NTDT patients with iron overload (LIC ≥ 5 mg Fe/g liver dw and SF ≥ 300 ng/mL) for up to 260 weeks.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Non-transfusion Dependent Thalassemia | Drug: deferasirox | Phase 4 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 134 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia |
| Actual Study Start Date : | December 6, 2012 |
| Actual Primary Completion Date : | January 3, 2015 |
| Actual Study Completion Date : | January 17, 2019 |
Resource links provided by the National Library of Medicine
Drug Information available for:
Deferasirox
| Arm | Intervention/treatment |
|---|---|
|
Deferasirox
All patients were treated with 10mg/kg/day deferasirox with dose adjustments after 4 weeks of treatment according to baseline Liver Iron Concentration (LIC).
|
Drug: deferasirox
Deferasirox dispersible tablets at strengths of 125 mg, 250 mg, and 500 mg were administered by oral daily dosing.
Other Name: ICL670 |
Primary Outcome Measures :
- Absolute Change in Liver Iron Content (LIC) at 52 Weeks From Baseline [ Time Frame: Baseline, 52 weeks ]Absolute change in liver iron concentration measured by MRI from baseline after 52 weeks of treatment
Secondary Outcome Measures :
- Percentage of Participants With Baseline LIC>15 Achieving LIC<5 mg Fe/g dw [ Time Frame: 5 years ]The percentage of participants with baseline LIC>15 mg Fe/g dw achieving an LIC <5 mg Fe/g dw during the study
- Time to Achieving LIC <5 mg Fe/g dw [ Time Frame: 5 years ]Time to achieving LIC <5 mg Fe/g dw for participants with baseline LIC>15 mg Fe/g dw during the study
- Time From Target LIC of 3 mg Fe/g dw to the First LIC ≥5 mg Fe/g dw in the Follow up Period [ Time Frame: post-baseline, up to 260 weeks ]Time from the target LIC <3 mg Fe/g dw to the first LIC ≥5 mg Fe/g dw in the follow-up period
- Absolute Change in Health-related Outcomes Using Medical Outcomes Study Form 36 (SF-36v2) [ Time Frame: Baseline, 52, 104 & 156 Weeks ]The SF-36 is a self-administered questionnaire for adults (from 18 years of age) and contains 36 items which measure: Physical functioning, Role limitation due to physical health problems, Bodily pain, General health perceptions, Vitality, Social functioning, Role limitations due to emotional problems and General mental health . The higher values indicate a better evaluation of health. Range: 0 to 100 [0 (worst possible health state measured by the questionnaire) to 100 (best possible health state)].
- Absolute Change in Health-related Outcomes Using the Pediatric Quality of Life Questionnaire (PedsQL™) [ Time Frame: Baseline, 52, 104 & 156 Weeks ]The PedsQL™ is a modular approach to measuring health-related quality of life (HRQOL) in children and adolescents. The 23-item PedsQL™ Generic Core Scales encompass the essential core domains for pediatric HRQOL measurement: 1) Physical Functioning (8 items), 2) Emotional Functioning (5 items), 3) Social Functioning (5 items), and 4) School Functioning (5 items). The Generic Core Scales are designed to enable comparisons across patient and healthy populations. The higher values indicate a better evaluation of health. Range: 0 to 100 [0 (worst possible health state measured by the questionnaire) to 100 (best possible health state)].
- Absolute Change in LIC From Baseline Over Time [ Time Frame: 24, 52, 76, 104, 128, 156, 180, 208, 232, 260 Weeks ]Absolute change in serum ferritin from baseline over time up to 260 weeks
- Serum Ferritin (SF) vs LIC at Baseline and EOS (Week 260 + 30 Days Follow-up) [ Time Frame: Baseline, End of Study (EOS): Week 260 + 30 days follow up ]Correlation between serum ferritin and LIC is assessed using scatter plots with pearson correlation coefficient and simple linear model.
- Correlation Analysis for Absolute Change in LIC and Serum Ferritin at Week 24 and EOS (Week 260 + 30 Days Follow-up) [ Time Frame: Week 24, End of Study (EOS): Week 260 + 30 days follow up ]Correlation for absolute change between LIC and serum ferritin was assessed using scatter plots with pearson correlation coefficient and simple linear model.
- Absolute Change in LIC From Baseline After 52 Weeks of Treatment by Underlying Non-transfusion Dependent Thalassemia (NTDT) Syndrome [ Time Frame: Baseline, 52 Weeks ]Absolute change in liver iron concentration measured by MRI from baseline after 52 weeks of treatment by underlying NTDT syndrome. The 4 underlying disease types: Beta-thalassemia intermedia (N =69), HbE beta-thalassemia (N = 24), Alpha-thalassemia intermedia (HbH disease) (N = 40), Other, specify (N = 1)
- Absolute Change in Serum Ferritin From Baseline After 52 Weeks [ Time Frame: Baseline, 52 weeks ]Absolute change in serum ferritin from baseline after 52 weeks of treatment
- PK Parameters: AUCtau [ Time Frame: pre-dose (0 hour), and at 2, and 4 hours at Week 4 ]The pharmacokinetic parameter, AUCtau was determined using non-compartmental method(s) for deferasirox and its iron complex. AUC=area under the concentration-time curve during a dosing interval at steady state (amount × time × volume).
- PK Parameters: Cmax [ Time Frame: pre-dose (0 hour), and at 2, and 4 hours at Week 4 ]The pharmacokinetic parameter, Cmax, was determined using non-compartmental method(s) for deferasirox and its iron complex. Cmax (maximum/peak plasma drug concentration after drug administration)=amount × volume
- PK Parameters: Tmax [ Time Frame: pre-dose (0 hour), and at 2, and 4 hours at Week 4 ]The pharmacokinetic parameter, Tmax, may be determined using non-compartmental method(s) for deferasirox and its iron complex. Tmax=time to reach maximum/peak concentration following drug administration.
- Plasma Pharmacokinetics (PK) Deferasirox Concentrations [ Time Frame: Weeks 12 & 24: pre-dose (0hr), 2hr & 4hr post-dose ]Blood samples for PK evaluation were collected for a sub-group of patients. The patient had to have been on treatment without dose adjustment or treatment interruption (for any reason) for at least 4 consecutive days prior to scheduled PK sampling visit. If there was a dosage change or interruption within 4 days of the visit, no PK blood samples was collected, and an appropriate comment had to be made on the PK CRF page.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 10 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Non-transfusion dependent congenital or chronic anemia inclusive of beta-thalassemia intermedia, HbE beta-thalassemia or alpha-thalassemia intermedia (HbH disease)/ Liver iron concentration >/= 5 mg Fe/g dw Serum Ferritin >/= 300 ng/mL
Exclusion Criteria:
HbS-beta Thalassemia, anticipated regular transfusion program during the study, blood transfusion 6 months prior to study start, significant proteinuria, creatinine clearance </= 40 ml/min, serum creatinine > ULN, ALT >5 x ULN, active hepatitis B or C, cirrhosis
Pediatrics Only:
A patient's weight of at least 20 kg is required to allow dosing of 5 mg/kg with one tablet of 125 mg
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01709838
Locations
| China, Guangxi | |
| Novartis Investigative Site | |
| Nanning, Guangxi, China, 530021 | |
| Greece | |
| Novartis Investigative Site | |
| Goudi-Athens, GR, Greece, 115 27 | |
| Italy | |
| Novartis Investigative Site | |
| Cagliari, CA, Italy, 09121 | |
| Novartis Investigative Site | |
| Milano, MI, Italy, 20122 | |
| Lebanon | |
| Novartis Investigative Site | |
| Hazmiyeh, Beirut, Lebanon, PO BOX 213 | |
| Thailand | |
| Novartis Investigative Site | |
| Bangkok, Thailand, 10700 | |
| Tunisia | |
| Novartis Investigative Site | |
| Tunis, Tunisia, 1006 | |
| Turkey | |
| Novartis Investigative Site | |
| Adana, Turkey, 01330 | |
| Novartis Investigative Site | |
| Istanbul, Turkey, 34093 | |
| Novartis Investigative Site | |
| Izmir, Turkey, 35040 | |
| United Kingdom | |
| Novartis Investigative Site | |
| London, United Kingdom, NW1 2PJ | |
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
| Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Study Documents (Full-Text)
Documents provided by Novartis ( Novartis Pharmaceuticals ):
Documents provided by Novartis ( Novartis Pharmaceuticals ):
Statistical Analysis Plan [PDF] January 23, 2019
Study Protocol [PDF] September 4, 2014
| Responsible Party: | Novartis Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT01709838 |
| Other Study ID Numbers: |
CICL670E2419 2012-000650-64 ( EudraCT Number ) |
| First Posted: | October 18, 2012 Key Record Dates |
| Results First Posted: | August 28, 2019 |
| Last Update Posted: | October 2, 2019 |
| Last Verified: | September 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com. |
| URL: | https://www.clinicalstudydatarequest.com |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
|
Non-transfusion dependent thalassemia NTDT deferasirox |
ICL670 LIC Liver Iron Concentration |
Additional relevant MeSH terms:
|
Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies |
Genetic Diseases, Inborn Deferasirox Iron Chelating Agents Chelating Agents Sequestering Agents Molecular Mechanisms of Pharmacological Action |